PARAMUS, N.J., November 6, 2019 – PGI Holding Corporation (PsychoGenics) announced that it has been awarded an Indefinite Delivery Indefinite Quantity contract by the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH), Department of Health and Human Services, for the screening of investigational agents through the “NINDS Preclinical Screening Platform for Pain” (PSPP). The maximum value of the contract is $49.9 million over a five-year ordering period. This project has been funded in whole or in part with Federal funds from NINDS, NIH, Department of Health and Human Services, under Contract Number 75N95019D00026. Read More.
PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer (CSO). This appointment reflects the Company’s growth in Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of proprietary technologies to support internal and partnered drug discovery and translational research. Read More.
PARAMUS, N.J., October 30, 2019 – PGI Drug Discovery LLC (PsychoGenics), announced today that it has received milestone payments from Sunovion Pharmaceuticals Inc. (Sunovion) associated with the advancement of two compounds into clinical testing - SEP-378614 and SEP-380135, bringing the total to four compounds now being studied in clinical trials for people living with neuropsychiatric conditions. Read More.
September 27, 2019 – Marlborough, Mass., and Paramus, N.J. , – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for SEP-363856, a novel agent for the treatment of adults and adolescents with schizophrenia. The global, multicenter program includes four studies that are designed to evaluate the safety, efficacy and tolerability of SEP-363856. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for SEP-363856 in May 2019. Read More.
May 10, 2019 – Marlborough, Mass., and Paramus, N.J., – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856, a novel agent for the treatment of people with schizophrenia. Read More.